SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Revolution Medicines, Inc. is a clinical-stage precision oncology company, which engages in developing novel targeted therapies. It engages in the discovery and development of cancer treatment by pioneering novel combination and monotherapy treatment regimens to maximize the depth and durability of clinical benefit and circumvent adaptive resistance mechanisms for patients which are dependent on the RAS and mTOR pathway. The company was founded by Mark A. Goldsmith, Kevan Shokat, Martin D. Burke, David L. Pompliano and Michael Fischbach in October 2014 and is headquartered in Redwood City, CA.

Revolution Medicines Inc

Revolution Medicines is gaining significant momentum as investors digest recent FDA Orphan Drug Designations and progress in late-stage Phase 3 clinical trials for its pancreatic cancer therapy. The community is actively discussing the stock's potential for a major re-rating, with analysts increasingly highlighting the company's robust pipeline and strategic importance in targeted oncology.

The Goldman Sachs Group, Inc. engages in the provision of financial services. It operates through the following business segments: Global Banking and Markets, Asset and Wealth Management, and Platform Solutions. The Global Banking and Markets segment includes investment banking, global investments, and equity and debt investments. The Asset and Wealth Management segment relates to the direct-to-consumer banking business which includes lending, deposit-taking, and investing. The Platform Solutions segment includes consumer platforms such as partnerships offering credit cards and point-of-sale financing, and transaction banking. The company was founded by Marcus Goldman in 1869 and is headquartered in New York, NY.

Goldman Sachs Group, Inc.

Goldman Sachs is trending due to the resignation of its top lawyer amid revelations of ongoing ties to Jeffrey Epstein, triggering a sharp decline in share price. Investors are also closely monitoring the bank's exposure to volatile credit markets and broader concerns regarding institutional stability during a period of geopolitical uncertainty.

Aeluma, Inc. engages in developing semiconductors for sensing, communication, and computing applications. The firm is also involved in manufacturing devices using compound semiconductor materials on large-diameter substrates that are commonly used to manufacture mass market microelectronics. The company was founded by Jonathan Klamkin and Lee McCarthy on February 28, 2019 and is headquartered in Goleta, CA.

Aeluma Inc

Aeluma is trending as investors weigh its potential for massive growth in silicon photonics against the execution risks associated with its transition from early-stage government contracts to commercial-scale manufacturing. Community sentiment is sharply divided between those bullish on its proprietary 300mm wafer technology as a high-reward play and those skeptical of its current revenue levels and recurring share offerings.

Maulcoin

Maulcoin is capturing attention as a community-driven meme project that is consistently trending on social platforms without an official chart, fueling intense community speculation about an upcoming breakout. Holders are actively discussing milestone targets for market capitalization and expressing strong commitment to the project's long-term growth and cultural branding.

RaveDAO is a global community uniting music, technology, and purpose. Since their first sold-out event at Dubai 2024, they have expanded across Europe, the Middle East, North America, and Asia, hosting world-class experiences with over 100,000 total attendees and 3,000+ attendees for each event.  RaveDAO has worked with top-tier artists like Vintage Culture, Don Diablo, Chris Avantgarde, Lilly Palmer, MORTEN, Bassjackers, and GENESI and has support from Binance, OKX, Bitget, and Polygon. RaveDAO is redefining live entertainment in Web3 and has active partnerships with 1001Tracklists, AMF, and Warner Music.  Beyond the dance floor, RaveDAO channels energy and attention toward impact. In 2025 alone, proceeds from its events helped restore sight to 400+ cataract patients in Nepal and fund over 150 meditation programs across the U.S.

RaveDAO

RaveDAO is experiencing significant market interest driven by a combination of high trading volume, a short squeeze, and momentum following its expansion and integration with the USD1-denominated ecosystem. While some community members are actively debating the token's long-term utility and governance, others are focused on its rapid price action and speculative potential as a trending Web3 entertainment protocol.

VanEck ETF Trust - VanEck Semiconductor ETF

VanEck Semiconductor ETF

The VanEck Semiconductor ETF is experiencing intense volatility and heightened scrutiny as traders debate whether current valuation levels represent a sustainable AI-driven growth cycle or an overheated bubble. The community is actively tracking a sharp divergence between high-flying hardware momentum and a struggling software sector, while aggressive options activity and short-dated put sweeps suggest that institutional players are bracing for significant downside risks.

IDEAYA Biosciences, Inc. engages in the research and development of oncology-focused precision medicine. The firm focuses on the targeted therapeutics for patients selected using molecular diagnostics. Its product candidate, IDE196, is a protein kinase C inhibitor for genetically defined cancers having GNAQ and GNA11 gene mutations. The company was founded by Yujiro S. Hata and Jeffrey Hager in June 2015 and is headquartered in South San Francisco, CA.

Ideaya Biosciences Inc

Ideaya Biosciences is surging following positive Phase 2/3 trial results for its metastatic uveal melanoma treatment, which significantly improved progression-free survival compared to standard therapies. Investors and the community are actively debating the potential for an accelerated FDA filing, while also closely watching for future pipeline updates and high institutional interest.

Spyre Therapeutics, Inc. is a clinical-stage biotechnology company, which engages in the development of next-generation human enzyme therapeutics as disruptive solutions for rare and other high-burden diseases. Its product, Pegzilarginase, is in a Phase 3 pivotal trial for the treatment of Arginase 1 Deficiency. The company was founded by George Georgiou and David G. Lowe on December 16, 2013 and is headquartered in Waltham, MA.

Spyre Therapeutics Inc.

Aeglea BioTherapeutics Inc

Spyre Therapeutics is seeing significant investor interest following positive clinical data for its SPY001 program, with the community actively discussing the company's multi-pathway platform approach and its potential to disrupt the IBD market. While some investors are focused on the long-term potential of its upcoming pipeline milestones, others remain cautious regarding the risks typically associated with clinical-stage biotechnology companies.

Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. Its portfolio includes TNX-102 SL, TNX-601, TNX-801, and TNX-1800. The company was founded by Seth Lederman and Donald W. Landry on November 16, 2007 and is headquartered in Berkeley Heights, NJ.

Tonix Pharmaceuticals Holding Corp

Tonix Pharmaceuticals is facing intense community debate as investors weigh concerns over potential dilution and future stock splits against optimism surrounding the commercial traction and insurance coverage expansion of their lead product, Tonmya. While some shareholders are selling amid downward price pressure and a history of capital raises, others are aggressively buying the dip, citing strong long-term pipeline fundamentals and recent insider share purchases as evidence of an impending turnaround.

Palantir Technologies, Inc. engages in the business of building and deploying software platforms that serve as the central operating systems for its customers. It operates through the Commercial and Government segments. The Commercial segment focuses on customers working in non-government industries. The Government segment is involved in providing services to customers that are the United States government and non-United States government agencies. Its platforms are widely used in areas such as defense, intelligence, healthcare, energy, and financial services, supporting data integration, large-scale analytics, and operational decision-making. The company was founded by Alexander Ceadmon Karp, Peter Andreas Thiel, Stephen Cohen, Joseph Lonsdale, and Nathan Dale Gettings in 2003 and is headquartered in Aventura, FL.

Palantir Technologies Inc - Ordinary Shares - Class A

Palantir Technologies Inc

Palantir is currently trading in a volatile spotlight following a combination of a high-profile endorsement from Donald Trump and intense short-selling pressure from investors like Michael Burry. The community remains deeply divided, with bulls pointing to the company's critical role in military AI and defense contracts, while bears raise significant concerns regarding its current valuation and rising competition from alternative AI models.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Tudor Investment Corp ET AL Raises Stock Position in NovoCure Limited $NVCR

Tudor Investment Corp ET AL boosted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 140.6% in the third quarter, according to its most recent filing with the SEC. The institutional...

JPMorgan Chase & Co. Buys 144,024 Shares of NovoCure Limited $NVCR

JPMorgan Chase & Co. lifted its stake in NovoCure Limited (NASDAQ:NVCR - Free Report) by 104.2% in the 3rd quarter, according to the company in its most recent Form 13F filing with the SEC. The firm...

SG Americas Securities LLC Boosts Position in NovoCure Limited $NVCR

SG Americas Securities LLC boosted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 905.6% in the fourth quarter, according to its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 278,806 shares of the medical equipment provider...

Novocure to Report First Quarter 2026 Financial Results

Novocure (NASDAQ: NVCR) will report financial results for the first quarter 2026 on April 30, 2026, before the U.S. financial markets open. Novocure management will host a conference call and webcast...

NovoCure Limited (NASDAQ:NVCR) Given Average Recommendation of "Hold" by Brokerages

Shares of NovoCure Limited (NASDAQ:NVCR - Get Free Report) have earned a consensus recommendation of "Hold" from the seven research firms that are covering the company, MarketBeat reports. One...

Humacyte, Inc. (HUMA) Reports Q4 Loss, Misses Revenue Estimates

Humacyte, Inc. (HUMA) delivered earnings and revenue surprises of -4.00% and -70.44%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

<ul class="summary-bullets"><li>Novocure stated that patients treated with its TTFields therapy simultaneously with atezolizumab, gemcitabine and nab-paclitaxel showed that the disease control rate was at 74.4%.</li><li>In contrast, patients who received only atezolizumab, gemcitabine and nab-paclitaxel had a disease control rate of 48%.</li><li>Among patients receiving TTFields therapy alongside atezolizumab and gem/nab-pac, the objective response rate was 34.6%, while the median overall survival was 9.7 months.</li></ul>Novocure (NVCR) shares gained nearly 3% in Thursday’s opening trade after the company announced positive topline results in its metastatic pancreatic cancer therapy trial.Novocure stated that&nbsp;PANOVA-4 met its pre-specified primary endpoint&nbsp;in the Phase 2 trial, achieving a statistically significant improvement in disease control rate. The PANOVA-4 study is a pilot, single-arm study of Tumor Treating Fields (TTFields) concomitant with atezolizumab, gemcitabine, and nab-paclitaxel as first-line treatment for metastatic pancreatic ductal adenocarcinoma (mPDAC).Retail sentiment on Stocktwits around&nbsp;<a href="https://stocktwits.com/symbol/NVCR">Novocure</a> trended in the ‘bullish’ territory. NVCR was among the top trending tickers on the platform at the time of writing.<h2 class="st-heading-2">Novocure Therapy Improves Disease Control Rate</h2>Novocure stated that patients treated with its TTFields therapy simultaneously with atezolizumab, gemcitabine and nab-paclitaxel showed that the disease control rate was at 74.4%.In contrast, patients who received only atezolizumab, gemcitabine and nab-paclitaxel had a disease control rate of 48%.“The positive results from the PANOVA-4 trial further support the potential of Tumor Treating Fields to improve outcomes in pancreatic cancer,” said Uri Weinberg, Chief Medical and Innovation Officer, Novocure.Secondary endpoints in PANOVA-4 included objective response rate (ORR) and overall survival (OS). Among patients receiving TTFields therapy alongside atezolizumab and gem/nab-pac, ORR was 34.6%, while median OS was 9.7 months.Additional secondary endpoints included progression-free survival, one-year survival rate, six-month progression-free survival, duration of response, and incidence of treatment-emergent adverse events.The company stated that TTFields therapy was well-tolerated, and device-related safety was consistent with prior clinical studies.<h2 class="st-heading-2">What Does Novocure Do?</h2>Novocure is a Switzerland-based company that is currently developing and commercializing its Tumor Treating Fields therapy. Its commercialized products have been approved in certain countries for the treatment of adult patients with glioblastoma, pancreatic cancer, non-small cell lung cancer, malignant pleural mesothelioma and pleural mesothelioma.<a href="https://stocktwits.com/symbol/NVCR">NVCR stock</a> is down 10% year-to-date and 38% over the past 12 months. The iShares Russell 2000 ETF (IWM) is up 22% over the past 12 months, while the Vanguard Small-Cap Growth Index Fund ETF Shares (VBK) is up 18%.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/trump-iran-begging-for-deal-warns-get-serious-on-talks-dow-futures-fall/cZ3ru8hRIjM">Trump Says Iran ‘Begging’ For Deal, Warns Them To 'Get Serious’ On Talks — Dow Futures Fall More Than 300 Points</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, NovoCure Limited logo is seen on a smartphone screen. (Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images)

NVCR Stock Gains After Novocure Announces Positive Topline Results In Metastatic Pancreatic Cancer Therapy Trial

Novocure stated that PANOVA-4 met its pre-specified primary endpoint in the Phase 2 trial, achieving a statistically significant improvement in disease control rate.

Equity

Novocure Announces Positive Topline Results from Phase 2 PANOVA-4 Clinical Trial of Tumor Treating Fields (TTFields) Therapy for Metastatic Pancreatic Cancer

Novocure (NASDAQ: NVCR) announced positive results today from the Phase 2 PANOVA-4 trial of Tumor Treating Fields (TTFields) therapy concomitant with atezolizumab (Tecentriq), gemcitabine and nab-paclitaxel (gem/nab-pac) as a first-line treatment for metastatic pancreatic ductal adenocarcinoma...

LENZ Therapeutics, Inc. (LENZ) Reports Q4 Loss, Misses Revenue Estimates

LENZ Therapeutics, Inc. (LENZ) delivered earnings and revenue surprises of -28.18% and -66.75%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?

Tudor Investment Corp ET AL Purchases 354,216 Shares of NovoCure Limited $NVCR

Tudor Investment Corp ET AL lifted its holdings in NovoCure Limited (NASDAQ:NVCR - Free Report) by 140.6% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 606,070 shares of the medical equipment provider's stock after purch...

NovoCure Ltd. is an oncology company which engages in the development, manufacture, and commercialization of Optune for the treatment of a variety of solid tumors. Its platform is called the Tumor Treating Field which uses electric fields tuned to specific frequencies to disrupt solid tumor cancer cell division. The company was founded by Yoram Palti in 2000 and is headquartered in St. Helier, Jersey.

NVCR
NovoCure Ltd

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest NVCR News

NVCRNovoCure Ltd